<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639599</url>
  </required_header>
  <id_info>
    <org_study_id>haloperidol</org_study_id>
    <nct_id>NCT01639599</nct_id>
  </id_info>
  <brief_title>Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients</brief_title>
  <official_title>Phase 4 Study of Optimal Dose of Haloperidol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low-dose haloperidol is known to be effective for the treatment of postoperative nausea and&#xD;
      vomiting (PONV). However, precise dose-response studies have not been completed, especially&#xD;
      in patients at high risk for PONV who require combination therapy. This study sought to&#xD;
      identify the optimal dose of haloperidol that could be combined with dexamethasone without&#xD;
      adverse effects in high-risk PONV patients receiving intravenous patient-controlled&#xD;
      anesthesia (IV PCA) after gynecological laparoscopic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female adults with three established PONV risk factors based on Apfel's score were randomised&#xD;
      into one of three study groups. At the end of anaesthesia, groups H0, H1, and H2 were given&#xD;
      intravenous (IV) saline, haloperidol 1 mg, and haloperidol 2 mg, respectively. All patients&#xD;
      were given dexamethasone during the induction of anaesthesia. The overall early (0-2 h) and&#xD;
      late (2-24 h) incidences of nausea, vomiting, rescue anti-emetic administration, pain, and&#xD;
      adverse effects (cardiac arrhythmias and extrapyramidal effects) were assessed&#xD;
      postoperatively. The sedation score was recorded in the postanaesthesia care unit (PACU).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Postoperative Nausea and Vomiting</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>incidence of nausea, vomiting and requirement for rescue antiemetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Extrapyramidal Symptoms</measure>
    <time_frame>postoperative 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cardiac Arrhythmia</measure>
    <time_frame>postoperative 2 hours</time_frame>
    <description>cardiac arrhythmia on continuous standard lead EKG monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation Change in Recovery Room</measure>
    <time_frame>postoperative 30, 60, 90, and 120 min</time_frame>
    <description>measurement of sedation change using a visual analogue scale (visual analogue scale; the minimum: 0 = widely awake and the maximum: 10 = maximally asleep)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Gynecological Disease</condition>
  <arm_group>
    <arm_group_label>dexamethasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dexamethasone 5mg iv during anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethasone, haloperiol 1mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethasone + haloperidol 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone iv injection</intervention_name>
    <description>Dexamethasone 5mg iv during anesthesia induction</description>
    <arm_group_label>dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, haloperidol</intervention_name>
    <description>dexamethasone + haloperidol 1mg</description>
    <arm_group_label>dexamethasone, haloperiol 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, haloperidol</intervention_name>
    <description>Active Comparator: dexamethasone + haloperidol 2mg</description>
    <arm_group_label>dexamethasone + haloperidol 2mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA physical status I or II women&#xD;
&#xD;
          -  Aged 20 65 years, and scheduled for gynecologic laparoscopic surgery and IV&#xD;
             patient-controlled analgesia (PCA) for postoperative pain control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or intolerance to the study drug&#xD;
&#xD;
          -  History of cardiac arrhythmia&#xD;
&#xD;
          -  Psychiatric illness&#xD;
&#xD;
          -  Chronic treatment with a dopamine antagonist&#xD;
&#xD;
          -  Use of opioids or steroids within one week of surgery&#xD;
&#xD;
          -  Use of antiemetic within 24 hours before the study&#xD;
&#xD;
          -  No ability to use the PCA device&#xD;
&#xD;
          -  Gastrointestinal, renal, or hepatic disease&#xD;
&#xD;
          -  Insulin-dependent diabetes or obesity with a body mass index &gt; 35 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Y.E. Moon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>associate proffesor</affiliation>
  </overall_official>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 4, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Young Eun Moon</investigator_full_name>
    <investigator_title>clinical associate professor</investigator_title>
  </responsible_party>
  <keyword>non-smoker</keyword>
  <keyword>female</keyword>
  <keyword>IV PCA</keyword>
  <keyword>patient-controlled analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone</title>
          <description>dexamethasone 5mg iv during anesthesia induction&#xD;
Dexamethasone iv injection: Dexamethasone 5mg iv during anesthesia induction</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone, Haloperiol 1mg</title>
          <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: dexamethasone + haloperidol 1mg</description>
        </group>
        <group group_id="P3">
          <title>Dexamethasone + Haloperidol 2mg</title>
          <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: Active Comparator: dexamethasone + haloperidol 2mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone</title>
          <description>dexamethasone 5mg iv during anesthesia induction&#xD;
Dexamethasone iv injection: Dexamethasone 5mg iv during anesthesia induction</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone, Haloperiol 1mg</title>
          <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: dexamethasone + haloperidol 1mg</description>
        </group>
        <group group_id="B3">
          <title>Dexamethasone + Haloperidol 2mg</title>
          <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: Active Comparator: dexamethasone + haloperidol 2mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Postoperative Nausea and Vomiting</title>
        <description>incidence of nausea, vomiting and requirement for rescue antiemetics</description>
        <time_frame>postoperative 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>dexamethasone 5mg iv during anesthesia induction&#xD;
Dexamethasone iv injection: Dexamethasone 5mg iv during anesthesia induction</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone, Haloperiol 1mg</title>
            <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: dexamethasone + haloperidol 1mg</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone + Haloperidol 2mg</title>
            <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: Active Comparator: dexamethasone + haloperidol 2mg</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Postoperative Nausea and Vomiting</title>
          <description>incidence of nausea, vomiting and requirement for rescue antiemetics</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Extrapyramidal Symptoms</title>
        <time_frame>postoperative 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>dexamethasone 5mg iv during anesthesia induction&#xD;
Dexamethasone iv injection: Dexamethasone 5mg iv during anesthesia induction</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone, Haloperiol 1mg</title>
            <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: dexamethasone + haloperidol 1mg</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone + Haloperidol 2mg</title>
            <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: Active Comparator: dexamethasone + haloperidol 2mg</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Extrapyramidal Symptoms</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Cardiac Arrhythmia</title>
        <description>cardiac arrhythmia on continuous standard lead EKG monitoring</description>
        <time_frame>postoperative 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>dexamethasone 5mg iv during anesthesia induction&#xD;
Dexamethasone iv injection: Dexamethasone 5mg iv during anesthesia induction</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone, Haloperiol 1mg</title>
            <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: dexamethasone + haloperidol 1mg</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone + Haloperidol 2mg</title>
            <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: Active Comparator: dexamethasone + haloperidol 2mg</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cardiac Arrhythmia</title>
          <description>cardiac arrhythmia on continuous standard lead EKG monitoring</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedation Change in Recovery Room</title>
        <description>measurement of sedation change using a visual analogue scale (visual analogue scale; the minimum: 0 = widely awake and the maximum: 10 = maximally asleep)</description>
        <time_frame>postoperative 30, 60, 90, and 120 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>dexamethasone 5mg iv during anesthesia induction&#xD;
Dexamethasone iv injection: Dexamethasone 5mg iv during anesthesia induction</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone, Haloperiol 1mg</title>
            <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: dexamethasone + haloperidol 1mg</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone + Haloperidol 2mg</title>
            <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: Active Comparator: dexamethasone + haloperidol 2mg</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Change in Recovery Room</title>
          <description>measurement of sedation change using a visual analogue scale (visual analogue scale; the minimum: 0 = widely awake and the maximum: 10 = maximally asleep)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>postoperative 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.3"/>
                    <measurement group_id="O2" value="4.7" spread="1.0"/>
                    <measurement group_id="O3" value="5.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postoperative 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.3"/>
                    <measurement group_id="O2" value="4.4" spread="1.0"/>
                    <measurement group_id="O3" value="5.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postoperative 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.4"/>
                    <measurement group_id="O2" value="4.0" spread="1.2"/>
                    <measurement group_id="O3" value="4.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postoperative 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.0"/>
                    <measurement group_id="O2" value="3.2" spread="1.1"/>
                    <measurement group_id="O3" value="4.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone</title>
          <description>dexamethasone 5mg iv during anesthesia induction&#xD;
Dexamethasone iv injection: Dexamethasone 5mg iv during anesthesia induction</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone, Haloperiol 1mg</title>
          <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 1mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: dexamethasone + haloperidol 1mg</description>
        </group>
        <group group_id="E3">
          <title>Dexamethasone + Haloperidol 2mg</title>
          <description>dexamethasone 5mg iv during anesthesia induction &amp; haloperidol 2mg iv 30 min before end of anesthesia&#xD;
Dexamethasone, haloperidol: Active Comparator: dexamethasone + haloperidol 2mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Young Eun Moon</name_or_title>
      <organization>Seoul St.Mary's Hospital,</organization>
      <phone>822-2258-6163</phone>
      <email>0910momo@naver.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

